

Available online on 15.04.2023 at <http://jddtonline.info>

Journal of Drug Delivery and Therapeutics

Open Access to Pharmaceutical and Medical Research

Copyright © 2023 The Author(s): This is an open-access article distributed under the terms of the CC BY-NC 4.0 which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited



Open Access Full Text Article



Review Article

Novel Applications of Hot Melt Extrusion Technology

Kumara Swamy Samanthula , Durgaprasad Kemiseti *, Jithendar Reddy Mandhadi , Chandrashekar Thalluri , Biplab Kumar Dey

Faculty of Pharmaceutical Science, Assam Down Town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, PIN-781026, India

Article Info:



Article History:

Received 17 Feb 2023
Reviewed 21 March 2023
Accepted 03 April 2023
Published 15 April 2023

Cite this article as:

Samanthula KS, Kemiseti D, Mandhadi JR, Thalluri C, Dey BK, Novel Applications of Hot Melt Extrusion Technology, Journal of Drug Delivery and Therapeutics. 2023; 13(4):154-158

DOI: <http://dx.doi.org/10.22270/jddt.v13i4.5794>

*Address for Correspondence:

Durgaprasad Kemiseti, Associate Professor, Faculty of Pharmaceutical Science, Assam Down Town University, Sankar Madhab Path, Gandhi Nagar, Panikhaiti, Guwahati, Assam, PIN-781026, India

Abstract

Hot melt extrusion (HME) technology was introduced to pharmaceuticals in the 1970s for manufacturing and product development. Since then, there were several developments in HME technology to utilize it effectively for the manufacturing of pharmaceuticals. Though the primary purpose of HME technology remains to be solubility enhancement through the preparation of amorphous solid dispersions, it also has various other applications like dry granulation, abuse-deterrent formulation, continuous manufacturing, film preparation, implants, sustained release formulations, etc. The purpose of this review article is to consolidate the information related to applications of HME technology in the pharmaceutical industry.

Keywords: Hot melt extrusion, poorly soluble drugs, continuous manufacturing, solid orals, and applications.

Introduction:

Hot melt extrusion (HME) technology initially used in the plastic industry was introduced into the pharmaceutical industry due to its widespread applications. Since its inception in the pharmaceutical industry, there have been several formulations that were developed with help of HME. HME also gained traction in the pharmaceutical industry due to recent recommendations of regulatory agencies to shift to continuous manufacturing from batch processing¹⁻⁵.

Typically, a hot melt extruder consists of feeding, processing and output region. The feeder is part of the extruder where incoming materials are introduced into the extruder for further processing. The processing region consists of a barrel and either a single screw or twin screws which rotate in the same direction or counter to each other facilitating the movement of materials through different sections⁶. The different sections of the processing region are maintained at different temperatures based on the requirement. The screws consist of a mixture of conveying and kneading blocks. As the name indicates, the conveying blocks help in transferring material from one zone to another zone. Kneading blocks based on their shape help in either dispersive mixing or distributive mixing^{7,8}.

The physicochemical properties of active ingredients and polymers play a decisive role in the selection of process parameters like screw speed, processing temperatures and screw configuration. Melting point and degradation

temperature are the major properties of the active ingredient which are considered in setting the process parameters. Likewise, glass transition temperature and melt viscosity are critical parameters in the selection of polymers for hot melt extrusion. Additives like plasticizers may be included in the formulation to improve the processability^{6,9}.

Several regulatory agencies have been encouraging continuous processes due to the robustness of the process due to low batch to batch variability. The hot melt extrusion process can be in the continuous manufacturing of pharmaceuticals due to its design and versatility in the preparation of various dosage forms. Several process analytical technologies (PAT) like in-line near-infrared (NIR) spectroscopy, UV/Vis spectroscopy, rheometry, etc. can be built into the extruder making it favorable for continuous manufacturing¹⁰⁻¹².

Applications of HME technology:

HME technology is used in the preparation of various dosage forms which help in solubility enhancement, abuse deterrence, implant preparation and others. The adaptability of the equipment to be modified makes it suitable to use as manufacturing equipment for films, implants, semi-solid dosage forms, etc. Case studies and relevant information has been discussed later to discuss the applicability of HME technology in the manufacturing of these dosage forms¹³.

Solubility Enhancement:

The oral route is the preferred route of drug delivery due to ease of administration, patient compliance, non-invasiveness and others. However, in order to be formulated as an oral route, the drug needs to have minimum solubility to reach systemic circulation. Unfortunately, most of the drugs suffer from poor aqueous solubility to be administered an oral route. In such cases, modifying the drug as amorphous solid dispersion or as co-crystals may be helpful in improving the solubility when alternate approaches like salt formation or pH modification are not possible¹⁴.

Amorphous Solid Dispersions (ASDs):

Amorphous solid dispersions are prepared by dispersing the sub-micron drug particles in hydrophilic polymers. Reduction in size results in the amorphization of drugs leading to increased entropy. Polymers prevent in agglomeration of these drug particles by arresting their movement.

Satish et al. prepared ASD of efavirenz, a low soluble anti-viral drug using HME technology, as an alternative to conventional and nanoformulations^{15, 16}. The dissolution rate of efavirenz was improved with polymers Eudragit EPO and Plasdone S-630. The extrudates were characterized by DSC, XRD and FTIR techniques. Dissolution studies indicate that the dissolution rate of ASDs was improved compared to the crystalline drug. FTIR studies indicate an interaction between the drug and Plasdone S-630 was responsible for the stability of the ASDs¹⁷.

Nimodipine belongs to a class of calcium channel blockers used in brain damage caused by subarachnoid hemorrhage. Nimodipine solid dispersion was prepared with hypromellose methyl succinate (H type) using HME technology. The ASDs were characterized using DSC, powder XRD, hot stage microscopy and SEM. The performance of ASDs was studied through in-vitro dissolution studies and in vivo pharmacokinetic studies in Sprague-Dawley rats. The results from these studies reveal improved solubility, dissolution rate and bioavailability with ASDs¹⁸.

In another study, ASDs of nifedipine and efavirenz prepared through HME technology using hydroxypropyl methylcellulose acetate succinate (HPMCAS) were investigated for processability, dissolution and stability. ASDs were studied through DSC and XRD techniques. Both techniques confirmed the amorphous nature of the drug in the ASDs and were found to be stable for three months at 40°C/75% RH¹⁹.

Another study on different grades of HPMCAS, Eudragit RSPO, Eudragit FS100, Kollidon VA64 and Plasdon K-29/32 was performed to study the supersaturation kinetics of nifedipine. Binary and ternary ASDs were prepared using the mentioned polymers. Solubility studies indicate that HPMCAS-HG and HPMCAS-HG + LG combinations of nifedipine resulted in the highest improvement in solubility and delay in induction of nucleation compared to ASDs of other polymers. Ternary ASDs of nifedipine/HPMCAS-LG/HPMCAS-HG, and nifedipine/HPMCAS-LG/Eudragit FS100 systems showed maintenance of supersaturation levels with enhanced dissolution due to synergistic effect²⁰.

Co-crystals:

Co-crystals are used to improve the solubility and dissolution rate of poorly soluble drugs. However, production of co-crystals requires large quantities of solvent and is a tedious process. HME technology can be used to manufacture pharmaceutical co-crystals through a grinding machine which could a solvent free-approach.

In a study, co-crystal of aripiprazole and adipic acid were manufactured using HME technology. Adipic acid acts as a co-

former. Soluplus was used at 5% to improve processability. The co-crystals were characterized through DSC, FTIR, NMR, p-XRD, SEM and hot-stage microscopy. FTIR spectra indicated the formation of new crystalline material through a non-covalent interaction between the drug and co-former²¹.

Meciej et al prepared co-crystals of theophylline and nicotinamide through a matrix-assisted co-crystallization approach. The effect of semi-crystalline and amorphous polymers on co-crystallization was studied. The results reveal that the use of a semi-crystalline polymer, poloxamer led to the formation of co-crystals embedded in a polymer matrix and increased the efficiency of the process. While the use of an amorphous polymer, Soluplus resulted in partially amorphous composites²².

Carvedilol co-crystals were produced using nicotinamide as a co-former through HME technology. The drug and nicotinamide ratio of 1:2 was selected and purged through HME by altering the barrel temperatures and shaft speed. The products were analyzed using different characterization techniques like DSC, PXRD, FTIR techniques and the shape of the co-crystal was studied using SEM. The solubility and dissolution rate of the co-crystals was compared with carvedilol. XRD results indicate that the 2θ value of the product was different from carvedilol suggesting drug-co-former interaction. The data also shows improvement in solubility and dissolution rate of carvedilol co-crystals compared to carvedilol²³.

Melt Granulation:

Melt granulation is performed by agglomeration of fed powders during the granulation process by modulating the barrel temperature below the melting temperature of API but above the glass transition temperature (T_g) or melting temperature of the binder used.

A high-dose modified-release tablet formulation of imatinib mesylate was prepared using melt granulation technology using a twin screw extruder. Hydroxypropyl cellulose (Klucel HF), Ethylcellulose and a combination of HPMC K100M and ethyl cellulose 100cP were used as polymers/binders for the study with magnesium stearate as a binder. A mixture of API and polymer was subjected to a processing temperature of 185°C which is below the melting point of the API. Confocal Raman spectroscopy was used to confirm that API remained in as crystalline state without melting²⁴.

Twin-screw melt granulation was utilized in improving the solubility of fenofibrate using Gelucire 48/16 as a solubilizer and Neusilin US2 as a surface adsorbent. Different granules were prepared based on altering the ratio of API, Gelucire 48/16 and Neusilin US2. The in vitro dissolution showed that an increase in Neusilin US2 levels resulted in a decrease in dissolution but improved stability. An increase in Gelucire 48/16 led to slower disintegration and dissolution²⁵.

Continuous manufacturing:

Continuous manufacturing is gaining attention in pharmaceutical manufacturing due to low batch to batch variability thereby improving the quality of the product²⁶. Twin screw extruders are already used in the continuous manufacturing of new commercial products like Orkambi, Prezista, etc. Several researchers have shifted the focus to developing pharmaceutical products through a continuous process using twin screw extruders²⁷.

Voriconazole topical cream was prepared using oil and a non-aqueous polyethylene base through a continuous process. A non-aqueous hydrophilic base was selected to prevent the degradation of voriconazole due to water. Transcutol P and a combination of camphor and menthol were studied as

permeation enhancers. The O/W cream was found to be stable for 3 months without degradation²⁸.

In another study, Oil in water emulgel was prepared by extrusion process. Lidocaine was used as a model drug. Several emulgels were prepared by altering the process variables like screw speed (100, 300 and 600 rpm) and barrel temperature (25°C and 60°C). The prepared emulgels were characterized for pH, water activity, globule size distribution, and *in vitro* release rate. It was found that higher screw speed resulted in smaller globules and higher drug release from emulgels compared to emulgels prepared at lower screw speed²⁹.

Films:

HME technology is also used in the preparation of buccal films. Buccal films can be used for local action and improving bioavailability by avoiding first-pass metabolism³⁰⁻³². Buccal films of clotrimazole were prepared using HME technology. A combination of HPMC and PEO was used as polymeric carriers and polycarbophil was used as bioadhesive material. A process temperature of 125-130°C was used for extrusion. The results indicate that the drug content and content uniformity of films were within the specifications. The films also possessed adequate bioadhesive strength³³.

3D Printing coupled HME technology:

Recently, HME technology was explored to produce personalized medicines by coupling 3D printing. The extrudates prepared through hot melt extrusion of drugs and polymers are used as starting material for 3D printing. Fused deposition modeling is used to prepare personalized medicines from extrudates like 3D printed microneedles, pediatric formulations, etc³⁴. Microneedles have certain advantages like to initiate quick action or improving bioavailability as they can directly route the drug into the systemic circulation³⁵.

Protein Drug Delivery:

Formulating protein drug delivery systems is challenging as proteins are prone to physical and chemical degradations³⁶. HME technology was explored to deliver a model protein lysozyme through protein/poly(lactide-co-glycolide) (PLGA) implants. Lysozyme stability was studied using DSC, FTIR, HPLC and biological activity. Formulations were optimized to have high drug loading. The optimized formulation was successful in delivering the lysozyme for a minimum of 60 days without initial bursting³⁷.

Nanoparticulate Drug Delivery:

Nanoparticles have several advantages improving solubility, improving bioavailability, targeting drug release capability, controlled drug release capability and others³⁸⁻⁴⁷. Fenofibrate solid lipid nanoparticles were prepared using HME technology using a quality-by-design approach. HME was used for melt emulsification and high-pressure homogenization was used for size reduction. The combination proved to produce SLNs with a consistent particle size of less than 200 nm. The *in vitro* release showed better release of SLNs prepared through combination and HME and high-pressure homogenization to micro fenofibrate formulation⁴⁸.

Conclusion:

HME technology since its advent into the pharmaceutical industry has been explored in the preparation of various dosage forms. Researchers are constantly trying to fill the gaps associated with specific drugs by employing novel technologies. In the years to come, HME technology may

replace some of the conventional technologies to produce pharmaceuticals with more quality.

Interest Declaration:

The authors declare that there is no conflict of interest.

References

- Patil H, Tiwari RV, Repka MA. Hot-melt extrusion: from theory to application in pharmaceutical formulation. *Aaps Pharmscitech*. 2016 Feb; 17:20-42. <https://doi.org/10.1208/s12249-015-0360-7>
- Palem CR, Dudhipala NR, Battu SK, Repka MA, Rao Yamsani M. Development, optimization and *in vivo* characterization of domperidone-controlled release hot-melt-extruded films for buccal delivery. *Drug development and industrial pharmacy*. 2016 Mar 3; 42(3):473-84. <https://doi.org/10.3109/03639045.2015.1104346>
- Crowley MM, Zhang F, Repka MA, Thumma S, Upadhye SB, Kumar Battu S, McGinity JW, Martin C. Pharmaceutical applications of hot-melt extrusion: part I. *Drug development and industrial pharmacy*. 2007 Jan 1; 33(9):909-26. <https://doi.org/10.1080/03639040701498759>
- Kallakunta VR, Sarabu S, Dudhipala N, Janga KY, Bandari S, Zhang F, Repka MA. Chrono modulated multiple unit particulate systems (MUPS) via a continuous hot melt double extrusion technique: Investigation of the formulation and process suitability. *European Journal of Pharmaceutics and Biopharmaceutics*. 2021 Nov 1; 168:184-94. <https://doi.org/10.1016/j.ejpb.2021.08.014>
- Thakkar R, Komanduri N, Dudhipala N, Tripathi S, Repka MA, Majumdar S. Development and optimization of hot-melt extruded moxifloxacin hydrochloride inserts, for ocular applications, using the design of experiments. *International Journal of Pharmaceutics*. 2021 Jun 15; 603:120676. <https://doi.org/10.1016/j.ijpharm.2021.120676>
- Ajjarapu S, Banda S, Basim P, Dudhipala N. Melt Fusion Techniques for Solubility Enhancement: A Comparison of Hot Melt Extrusion and KinetiSol® Technologies. *Scientia Pharmaceutica*. 2022 Aug 24; 90(3):51. <https://doi.org/10.3390/scipharm90030051>
- Rao RR, Pandey A, Hegde AR, Kulkarni VI, Chincholi C, Rao V, Bhushan I, Mutalik S. Metamorphosis of Twin Screw Extruder-Based Granulation Technology: Applications Focusing on Its Impact on Conventional Granulation Technology. *AAPS PharmSciTech*. 2022 Jan; 23:1-23. <https://doi.org/10.1208/s12249-021-02173-w>
- Vynckier AK, Dierickx L, Voorspoels J, Gonnissen Y, Remon JP, Vervaeck C. Hot-melt co-extrusion: requirements, challenges and opportunities for pharmaceutical applications. *Journal of pharmacy and pharmacology*. 2014 Feb; 66(2):167-79. <https://doi.org/10.1111/jphp.12091>
- Censi R, Gigliobianco MR, Casadidio C, Di Martino P. Hot melt extrusion: Highlighting physicochemical factors to be investigated while designing and optimizing a hot melt extrusion process. *Pharmaceutics*. 2018 Jul 11; 10(3):89. <https://doi.org/10.3390/pharmaceutics10030089>
- Maniruzzaman M, Nokhodchi A. Continuous manufacturing via hot-melt extrusion and scale up: regulatory matters. *Drug discovery today*. 2017 Feb 1; 22(2):340-51. <https://doi.org/10.1016/j.drudis.2016.11.007>
- Schlindwein W, Bezerra M, Almeida J, Berghaus A, Owen M, Muirhead G. In-line UV-Vis spectroscopy as a fast-working process analytical technology (PAT) during early phase product development using hot melt extrusion (HME). *Pharmaceutics*. 2018 Sep 23; 10(4):166. <https://doi.org/10.3390/pharmaceutics10040166>
- Martin C. Continuous mixing of solid dosage forms via hot-melt extrusion. *Pharmaceutical Technology*. 2008 Oct 2; 32(10).
- Repka MA, Majumdar S, Kumar Battu S, Srirangam R, Upadhye SB. Applications of hot-melt extrusion for drug delivery. *Expert*

- opinion on drug delivery. 2008 Dec 1; 5(12):1357-76. <https://doi.org/10.1517/17425240802583421>
14. Savjani KT, Gajjar AK, Savjani JK. Drug solubility: importance and enhancement techniques. *International Scholarly Research Notices*. 2012; 2012. <https://doi.org/10.5402/2012/195727>
 15. Thota SK, Dudhipala N, Katla V, Veerabrahma K. Cationic Solid SMEDDS of Efavirenz for Improved Oral Delivery: Development by Central Composite Design, In Vitro and In Vivo Evaluation. *AAPS PharmSciTech*. 2023 Jan 18; 24(1):38. <https://doi.org/10.1208/s12249-022-02495-3>
 16. Karri V, Butreddy A, Dudhipala N. Fabrication of efavirenz freeze dried nanocrystals: formulation, physicochemical characterization, in vitro and ex vivo evaluation. *Advanced Science, Engineering and Medicine*. 2015 May 1; 7(5):385-92. <https://doi.org/10.1166/asem.2015.1710>
 17. Sathigari SK, Radhakrishnan VK, Davis VA, Parsons DL, Babu RJ. Amorphous-state characterization of efavirenz-polymer hot-melt extrusion systems for dissolution enhancement. *Journal of pharmaceutical sciences*. 2012 Sep 1; 101(9):3456-64. <https://doi.org/10.1002/jps.23125>
 18. Zhang Q, Zhao Y, Zhao Y, Ding Z, Fan Z, Zhang H, Liu M, Wang Z, Han J. Effect of HPMCAS on recrystallization inhibition of nimodipine solid dispersions prepared by hot-melt extrusion and dissolution enhancement of nimodipine tablets. *Colloids and Surfaces B: Biointerfaces*. 2018 Dec 1; 172:118-26. <https://doi.org/10.1016/j.colsurfb.2018.08.030>
 19. Sarabu S, Kallakunta VR, Bandari S, Batra A, Bi V, Durig T, Zhang F, Repka MA. Hypromellose acetate succinate based amorphous solid dispersions via hot melt extrusion: Effect of drug physicochemical properties. *Carbohydrate polymers*. 2020 Apr 1; 233:115828. <https://doi.org/10.1016/j.carbpol.2020.115828>
 20. Butreddy A, Sarabu S, Almutairi M, Ajjarapu S, Kolimi P, Bandari S, Repka MA. Hot-melt extruded hydroxypropyl methylcellulose acetate succinate based amorphous solid dispersions: Impact of polymeric combinations on supersaturation kinetics and dissolution performance. *International Journal of Pharmaceutics*. 2022 Mar 5; 615:121471. <https://doi.org/10.1016/j.ijpharm.2022.121471>
 21. Butreddy A, Sarabu S, Bandari S, Dumpa N, Zhang F, Repka MA. Polymer-assisted aripiprazole-adipic acid cocrystals produced by hot melt extrusion techniques. *Crystal growth & design*. 2020 Jun 2; 20(7):4335-45. <https://doi.org/10.1021/acs.cgd.0c00020>
 22. Gajda M, Nartowski KP, Pluta J, Karolewicz B. Tuning the cocrystal yield in matrix-assisted cocrystallisation via hot melt extrusion: a case of theophylline-nicotinamide cocrystal. *International Journal of Pharmaceutics*. 2019 Oct 5; 569:118579. <https://doi.org/10.1016/j.ijpharm.2019.118579>
 23. Fernandes GJ, Rathnanand M, Kulkarni V. Mechanochemical synthesis of carvedilol cocrystals utilizing hot melt extrusion technology. *Journal of Pharmaceutical Innovation*. 2019 Dec; 14:373-81. <https://doi.org/10.1007/s12247-018-9360-y>
 24. Vasanthavada M, Wang Y, Haefele T, Lakshman JP, Mone M, Tong W, Joshi YM, Serajuddin AT. Application of melt granulation technology using twin-screw extruder in development of high-dose modified-release tablet formulation. *Journal of pharmaceutical sciences*. 2011 May 1; 100(5):1923-34. <https://doi.org/10.1002/jps.22411>
 25. Sarabu, S., Kallakunta, V.R., Butreddy, A., Janga, K.Y., Ajjarapu, S., Bandari, S., Zhang, F., Murthy, S.N. and Repka, M.A.. A one-step twin-screw melt granulation with gelucire 48/16 and surface adsorbent to improve the solubility of poorly soluble drugs: effect of formulation variables on dissolution and stability. *AAPS PharmSciTech*, 2021; 22:1-14. <https://doi.org/10.1208/s12249-021-01945-8>
 26. Ajjarapu S, Rangappa S, Shankar VK, Shettar A, Kumar HS, Kulkarni VI, Repka MA, Murthy SN. A rapid tool to optimize process variables for continuous manufacturing of metronidazole ointment using melt extrusion technique. *AAPS PharmSciTech*. 2020 Oct; 21:1-7. <https://doi.org/10.1208/s12249-020-01808-8>
 27. Price GA, Mallik D, Organ MG. Process analytical tools for flow analysis: a perspective. *Journal of Flow Chemistry*. 2017 Sep; 7(3-4):82-6. <https://doi.org/10.1556/1846.2017.00032>
 28. Shettar A, Shankar VK, Ajjarapu S, Kulkarni VI, Repka MA, Murthy SN. Development and characterization of Novel topical oil/PEG creams of voriconazole for the treatment of fungal infections. *Journal of Drug Delivery Science and Technology*. 2021 Dec 1; 66:102928. <https://doi.org/10.1016/j.jddst.2021.102928>
 29. Echanur VA, Matadh AV, Pragathi SG, Sarasija S, Thean Y, Badruddoza AZ, Shah J, Kulkarni V, Ajjarapu S, Reena NM, Shivakumar HN. Continuous Manufacturing of Oil in Water (O/W) Emulgel by Extrusion Process. *AAPS PharmSciTech*. 2023 Mar 10; 24(3):76. <https://doi.org/10.1208/s12249-023-02530-x>
 30. Palem CR, Kumar Battu S, Maddineni S, Gannu R, Repka MA, Yamsani MR. Oral transmucosal delivery of domperidone from immediate release films produced via hot-melt extrusion technology. *Pharmaceutical development and technology*. 2013 Feb 1; 18(1):186-95. <https://doi.org/10.3109/10837450.2012.693505>
 31. Jaipal A, Pandey MM, Charde SY, Sadhu N, Srinivas A, Prasad RG. Controlled release effervescent buccal discs of buspirone hydrochloride: in vitro and in vivo evaluation studies. *Drug delivery*. 2016 Feb 12; 23(2):452-8. <https://doi.org/10.3109/10717544.2014.917388>
 32. Palem, C.R., Dudhipala, N., Battu, S.K., Goda, S., Repka, M.A. and Yamsani, M.R. Combined dosage form of pioglitazone and felodipine as mucoadhesive pellets via hot melt extrusion for improved buccal delivery with application of quality by design approach. *Journal of Drug Delivery Science and Technology*, 2015; 30:209-219. <https://doi.org/10.1016/j.jddst.2015.10.017>
 33. Singh S, Jain S, Muthu MS, Tiwari S, Tilak R. Preparation and evaluation of buccal bioadhesive films containing clotrimazole. *Aaps PharmSciTech*. 2008 Jun; 9:660-7. <https://doi.org/10.1208/s12249-008-9083-3>
 34. Deshkar S, Rathi M, Zambad S, Gandhi K. Hot melt extrusion and its application in 3D printing of pharmaceuticals. *Current Drug Delivery*. 2021 May 1; 18(4):387-407. <https://doi.org/10.2174/1567201817999201110193655>
 35. Maurya A, Rangappa S, Bae J, Dhawan T, Ajjarapu SS, Murthy SN. Evaluation of soluble fentanyl microneedles for loco-regional antinociceptive activity. *International journal of pharmaceutics*. 2019 Jun 10; 564:485-91. <https://doi.org/10.1016/j.ijpharm.2019.04.066>
 36. Butreddy A, Janga KY, Ajjarapu S, Sarabu S, Dudhipala N. Instability of therapeutic proteins-An overview of stresses, stabilization mechanisms and analytical techniques involved in Lyophilized proteins. *International journal of biological macromolecules*. 2021 Jan 15; 167:309-25. <https://doi.org/10.1016/j.ijbiomac.2020.11.188>
 37. Ghalanbor Z, Körber M, Bodmeier R. Improved lysozyme stability and release properties of poly (lactide-co-glycolide) implants prepared by hot-melt extrusion. *Pharmaceutical research*. 2010 Feb; 27:371-9. <https://doi.org/10.1007/s11095-009-0033-x>
 38. Muddineti OS, Kumari P, Ajjarapu S, Lakhani PM, Bahl R, Ghosh B, Biswas S. Xanthan gum stabilized PEGylated gold nanoparticles for improved delivery of curcumin in cancer. *Nanotechnology*. 2016 Jun 27; 27(32):325101. <https://doi.org/10.1088/0957-4484/27/32/325101>
 39. Dudhipala N, Veerabrahma K. Pharmacokinetic and pharmacodynamic studies of nisoldipine-loaded solid lipid nanoparticles developed by central composite design. *Drug development and industrial pharmacy*. 2015 Dec 2; 41(12):1968-77. <https://doi.org/10.3109/03639045.2015.1024685>
 40. Mallesh K, Pasula N, Kumar Ranjith CP. Piroxicam proliposomal gel: a novel approach for tropical delivery. *Journal of Pharmacy Research*. 2012; 5(3):1755-63.
 41. Nagaraj K, Narendar D, Kishan V. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability. *Drug development and*

- industrial pharmacy. 2017 Jul 3; 43(7):1186-96.
<https://doi.org/10.1080/03639045.2017.1304955>
42. Basim P, Gorityala S, Kurakula M. Advances in functionalized hybrid biopolymer augmented lipid-based systems: A spotlight on their role in design of gastro retentive delivery systems. Archives of Gastroenterology Research. 2021 Mar 2; 2(1):35-47.
<https://doi.org/10.33696/Gastroenterology.2.025>
43. Butreddy A, Kommineni N, Dudhipala N. Exosomes as naturally occurring vehicles for delivery of biopharmaceuticals: insights from drug delivery to clinical perspectives. Nanomaterials. 2021 Jun 3; 11(6):1481. <https://doi.org/10.3390/nano11061481>
44. Youssef AA, Cai C, Dudhipala N, Majumdar S. Design of topical ocular ciprofloxacin nanoemulsion for the management of bacterial keratitis. Pharmaceuticals. 2021 Mar 3; 14(3):210.
<https://doi.org/10.3390/ph14030210>
45. Kurakula M, Patel DB, Patel B, Gorityala S, Basim P. Functionalized Nanocarriers for Drug delivery: Amalgam of Biopolymers and Lipids. J Nanomed. 2021; 4(1):1037.
46. Dudhipala N. A comprehensive review on solid lipid nanoparticles as delivery vehicle for enhanced pharmacokinetic and pharmacodynamic activity of poorly soluble drugs. International Journal of Pharmaceutical Sciences and Nanotechnology (IJPSN). 2019 Mar 31; 12(2):4421-40.
<https://doi.org/10.37285/ijpsn.2019.12.2.1>
47. Samanthula KS, Alli R, Gorre T. Preliminary Studies on Optimization of Anti-Parkinson Drug Loaded Lipid Nanoparticles Enriched Hydrogel Formulations for Management of Parkinson's Disease. Current Nanomedicine (Formerly: Recent Patents on Nanomedicine). 2021 Jul 1; 11(2):112-26.
<https://doi.org/10.2174/2468187311666210311114908>
48. Patil H, Feng X, Ye X, Majumdar S, Repka MA. Continuous production of fenofibrate solid lipid nanoparticles by hot-melt extrusion technology: a systematic study based on a quality by design approach. The AAPS journal. 2015 Jan; 17:194-205.
<https://doi.org/10.1208/s12248-014-9674-8>